



INVESTIGACIÓN PARA
OTRA OPORTUNIDAD

CRIS

TRANSLATIONAL PHYSICIAN PROGRAMME

Call for Applications 2025

TABLE OF CONTENTS

INTRODUCTION	3
CALL FOR APPLICATIONS	3
PROGRAMME RESOURCES	4
REQUIREMENTS FOR APPLICANTS	5
DOCUMENTATION REQUIRED FOR THE APPLICATION	7
SELECTION PROCESS	9
GENERAL EVALUATION CRITERIA	11
APPEALS	12
APPOINTMENT	12
INCOMPATIBILITIES	13
OBLIGATIONS	14
DATA PROTECTION AND PRIVACY	15
OBSERVATIONS	16

Introduction

CRIS Cancer is keenly aware of the difficulty faced by clinicians who want to develop independent research in Spain, mainly due to their care workload and the difficulties of implementing projects, which undoubtedly slows down progress in our knowledge of the disease and treatment for cancer patients.

CRIS Cancer is calling for applications to its **CRIS Translational Physician Programme** to train outstanding physicians of any nationality who wish to develop their research career in hospitals in Spain so that they can become outstanding cancer researchers.

Candidates must be specialist clinicians with some research experience and with the potential to develop transformative research and the capacity to lead a research group.

The aim of the **CRIS Translational Physician Programme** is to provide competitive financial conditions and incentives for these clinical researchers to develop their career in Spain.

Call for Applications

Every year, CRIS Cancer runs a programme to award **2 research grants** as part of the **CRIS Translational Physician Programme**, each covering a **five-year period**, for the purposes of recruiting clinical scientists to develop their activity at any hospital, university and/or research centre in Spain.

The programme invites applications from all specialist physicians who have completed a doctorate in the last ten years prior to the year in which this call is published (i.e., after January 2015).

Candidates' care workload may not under any circumstances exceed 50% of their working day and may be increased up to 100% of their working day.

With the support of the host institution, candidates should devote a minimum of 50% of their research time to this project.

The candidate does not necessarily need to be employed by the receiving institution at the time of application. However, the institution must indicate in a letter that it accepts the candidate to carry out his or her activities there.

The programme will effectively begin when the management of the hospital or research centre confirms it has hired or allocated time for the candidate to conduct research, or when it is confirmed that the candidate has been brought into the host hospital or research centre, in the event that they are moving to a new centre.

Beneficiaries must accept their place on the programme between **1st February and 30th June 2026**. Under duly justified circumstances, their incorporation may be delayed until 31 September 2026. The start date must be communicated to CRIS Cancer prior to that date. In duly justified cases of major force, this incorporation could be postponed. Each case will be assessed by CRIS on an individual basis. CRIS reserves the right to move the position or even leave it vacant if the beneficiaries do not meet the requirements for incorporation or the time until incorporation is too long.

The **programme runs initially for three years and may be renewed for a further two years** up to a maximum of five years, provided that the progress reports requested annually, and the **mid-term evaluation carried out after the second year** are favourable.

The call for applications opens on **1 March 2025** and closes on **14 May 2025** at 23:59 (Central European Time - CET).

Programme resources

The maximum grant awarded will be **€400,000**, which will be spread over **five annual instalments of up to €80,000** a year, which include:

a. **Salary:** Labour contract, which includes social security contributions and any other contributions payable by the institution, as well as the beneficiary's gross remuneration. The following options are contemplated:

- **Salary supplement** up to a maximum of €70,000 per annum. If the candidate is part of a programme to attract talent such as the Ramón y Cajal, Juan de la Cierva, Juan Rodés, Río Hortega or Miguel Servet programmes, there is a possibility to supplement their salary up to €60,000 and devote the rest to cover costs associated with the project.
- **Intensification** of between 50% and 100% of the candidate's working hours. The endowment will cover the costs incurred by the institution hosting the programme beneficiary.
- In the case of a **new hire** and if the physician is not involved in clinical practice, i.e., is dedicated exclusively to research, the **CRIS Translational Physician Programme** provides the possibility for candidates to fully cover their recruitment costs up to a maximum of €70,000 gross per year.
- cover **costs associated with the project**.

b. **Costs associated with the research project**, including:

- Recruitment of staff linked to the development of the project.
- Acquisition and maintenance of scientific equipment and consumables.
- Travel costs and associated expenses, registration fees at congresses, seminars, and scientific conferences.
- Management costs for industrial and intellectual property rights related to the project, costs of patents.
- Other expenses related to the development of the project.
- Travel costs associated with the trip to the CRIS Cancer annual event.

Note:

- For a new hired candidate that receives a full gross salary of €70,000, the available funds for the project expenses will be up to €10,000.
- For a candidate that receives a salary supplement or intensification of their working hours, this maximum funds for the project expenses will be €80,000.

c. **Moving assistance (optional)** of €5,400 to cover the cost of relocating to the city at the start of the programme, for beneficiaries who are joining a new centre from another city. These funds will be deducted from the costs associated with the project.

- d. **Family support (optional)** of €1,200 gross per annum for each of the researcher's dependent children, up to a maximum of €2,400 and as long as they are under 18 years of age (or can prove a certificate of dependency). Family support will be determined on the date the researcher joins the centre and will be reviewed annually at the time of programme renewal. This amount will be subtracted from the programme's annual budget, and its implementation will be adjusted to the administrative particularities of each institution.

The annual amounts proposed in the budget may not exceed a maximum of €80,000 per year. It is possible that part of the funds may be carried over to subsequent years because the planned expenditure has not been incurred, but this must be duly justified in the budget of the annual report.

In **no case may indirect costs** associated with the project be applied by the recipient institution.

These amounts will be subject to the corresponding legal tax retention.

CRIS Cancer will sign an agreement with the host hospital, which will receive the programme allowance directly and must fully cover all expenses derived from the programme.

The contractual relationship between the applicant and the hospital shall comply with the provisions of the legislation in force at any given time.

The researcher is the named recipient of the funding and shall be recruited by the host institution.

Requirements for applicants

Training

Applications will be accepted from specialist physicians who have **completed a Doctorate in the ten years prior to the deadline of the call for applications** (since January 2015). The date on which the candidate defended their PhD thesis will be taken as the date on which they completed their PhD and earned the title of doctor. Therefore, a document must be provided that accredits the date on which the candidate defended their thesis. In the event that the applicant holds more than one doctorate, the above period will be calculated on the basis of the first title obtained. Applications will be accepted if the thesis reading date is scheduled before October 2025. If on 1 October 2025 the candidate cannot provide a valid doctoral degree, the application will be rejected.

These periods can be extended should any of the circumstances described in the "Observations" section apply, provided they are suitably accredited and documented.

Research Career

The candidate **must be the first or last author for, at least, 1 publication in Q1 journals**. Only articles with a Pubmed ID will be considered. The classification of the journal in the first quartile will be verified using the last published Journal of Citation Report list as the criterion. When calculating the total number of publications, abstracts from congresses shall not be taken into account, neither will preprints, articles submitted or in review, or book chapters.

Nationality

The **CRIS Translational Physician Programme** is open to post-doctoral clinical scientists of all nationalities as long as their project is carried out at a centre in Spain.

Project

Candidates must provide an overview of the research line associated with the call for applications and which will be the object of the funding associated with the programme. The project should demonstrate a high level of scientific and technical quality.

In case the candidate has applied to the **CRIS Investigator / Clinical / Translational Physician Talent Programme** on at least two previous occasions with the same project, the candidate may apply only if he/she submits a different proposal.

Mentor

The candidate must propose a mentor and provide his/her background with the application.

There can only be 1 mentor proposed per application.

This mentor need not necessarily be a supervisor of the project, but rather a reference figure to guide the candidate in achieving his/her scientific and career goals.

This mentor can be from any institution, including those outside Spain. In case that the mentor works in the hosting institution, the mentor should facilitate the professional development of the researcher and the project at the institution, and guarantee that the candidate can dedicate the appropriate time to develop the project.

The same mentor can appear in several applications.

Hosting Institution

The Hosting Institution must be located in Spain. Only hospitals, universities, and research centres in Spain can be the beneficiary of the **CRIS Translational Physician Programme**.

Several applications may be submitted from the same institution.

For each call there can only be one beneficiary of this programme per institution.

Restrictions

The following restrictions apply to the submission of applications:

- A researcher **may apply just to one CRIS Research Programme (CRIS Excellence, Emerging Leader, or Translational Physician Programme)** in the same call for applicants.
- An applicant that has been **awarded** in any previous CRIS Research Programme's call for applicants **cannot reapply to the same CRIS Research Programme**. He/she may only apply to a **different CRIS Research Programme during the last year of the grant**. So, only the awardees of the CRIS Out-Back Programme call at 2021 could apply to the **CRIS Translational Physician Programme** call for applicants 2025.
- Only hospitals, universities, and research centres in Spain can be the beneficiary of the **CRIS Translational Physician Programme**.

- In each call there can only be one beneficiary of the CRIS Translational Physician Programmes per institution.
- Members of the scientific evaluation board will not be able to apply for these programmes.
- If an applicant has been rejected previously due to a lack of scientific integrity, they may not reapply.

Documentation required for the application

Candidates or their institutions may raise any question about the **CRIS Translational Physician Programme** call for applications, at www.criscancer.org/programascris or emailing convocatorias@criscancer.org.

All applications must be completed on-line using the **CRIS Translational Physician Programme Platform**, which will be made available to candidates at www.criscancer.org/programascris during the application submission period for the 2025 programme. Applicants must register as users on the platform, which will send them an email confirmation allowing them to access their application.

All applications must provide two blocks of documentation, which **must be completed entirely in English**.

Part A: Administrative Form

Part B: Documentation

Part A: ADMINISTRATIVE FORM

This questionnaire is accessed through the application on the candidate website. You will not be able to fill in the rest of the documentation without first completing this form. This section must be **filled out entirely in English**.

The form includes the following elements:

- General information about the candidate:** Name and surname, identification document, year of birth, academic degree, and contact information.
- Details about the current institution:** Name and address
- Details about the host institution:** Name and address
- Details of the mentor:** First and last name, institution, and contact details.
- Details of the Research Project:** Title, code, research area, type of cancer, topic, and duration.

Part B: DOCUMENTATION

The templates for several of the documents in this section are provided on the candidacy website and the platform. These templates must be used; any other format will not be accepted. Each page will have a header indicating the name of the candidate and an acronym for their candidacy. This section must be filled out **entirely in English**. None of the documents may exceed 4 Mb in size.

- Curriculum vitae** of the candidate using a standardised summarised format (**CVA, in its 4-page format**), following an abbreviated template of standard forms for public calls for applications

(<https://cvn.fecyt.es/>). This document must be provided **in English**. The FECYT or Instituto de Salud Carlos III templates are valid.

- b. **Doctoral certificate** and the date on which the candidates defended their PhDs. If the applicant does not have this certificate, you must provide an official document stating the date on which the doctorate was awarded.
- c. If you have requested an **extension for the validity of your candidacy** on account of matters such as illness, parental leave, military service, or other causes, you must attach documentation that accredits such circumstances. The accepted circumstances are in the Observations section, at the end of this document.
- d. **Research Project**. The provided **template** must be used (**Maximum 5 pages**).

The report must not exceed 5 pages. The bibliography and figures do not count for the maximum number of pages. The format of the text should be as follows:

- Din A4.
- Nunito, Calibri, Times New Roman, Arial or Helvetica.
- Font size 11 or 12.
- Single line spacing.
- Margins: 2 cm on either side.

- f. **Project budget**. The provided excel **template** must be used. A **financial external audit** at the end of the project may be included in the budget. Indirect costs cannot be included.
- e. **Candidate's track record**, reflecting key events in the researcher's career and the candidate's experience in the field of study. The provided **template** must be used (**Maximum 3 pages**).
- f. **Letter of acceptance from the Mentor** pledging to support the future development of the candidate's research activity in the project area and at the proposed institution. The provided **template** must be used.
- g. **Curriculum vitae of the Mentor** using a standardised summarised format and an abbreviated template of standard forms for public calls for applications (CVA). This document must be provided **in English**.
- h. **Letter of acceptance from the host institution** signed by the managing director or scientific director of the centre guaranteeing institutional support for the researcher and the research line of the particular project. This document is indispensable for a candidacy to be validated. The **template** provided must be used.
- i. **Declaration on ethical issues**. The provided **template** must be used.
- j. **One-page summary**, in Spanish, to explain the project in terms that a patient can understand. The provided **template** must be used.

Documents uploaded to the platform in PDF format must be clear and legible. In addition, each page of the original document must correspond to a page of the PDF document. These documents may be provided in the language in which they were issued, but if they are in a language other than English or Spanish, they must be accompanied by a certified translation.

The candidates selected as beneficiaries shall be given a reasonable amount of time to confirm their interest in the centre or unit they indicated as their first option. During this time, they will also be able to

explore alternative possibilities that might be better suited to their personal project. However, they must inform CRIS Cancer of these changes and obtain its agreement.

In any case, the research line selected by the candidate to carry out their research project, if different from the area stipulated originally in their application, must not be too far removed from their initial preference, in terms of content, field or discipline. They must inform CRIS Cancer of these changes and obtain its agreement.


Selection process

The selection process is designed to identify outstanding candidates regardless of their origin, gender, nationality, or other aspects that could skew the selection. The goal is to ensure transparency, fairness, and impartiality throughout the process.

The members of the screening and selection committee choose candidates who, according to their own criteria, provide evidence of the greatest merits and abilities.

Stages of evaluation and expert panels

All applications that meet the necessary conditions will be evaluated by expert scientists.



There are three independent rounds of evaluation:

1. Administrative Evaluation. Eligibility Check.

When evaluating eligibility, all applications received will be evaluated by the CRIS cancer Scientific Office, and those that do not meet the **criteria and requirements** set out in the terms and conditions of the call for applications will be rejected.

There will then be a period during which any outstanding documentation will be requested, or any corrections or clarifications should be made.

All rejected applications will receive an email detailing the reason for rejection.

2. Second Evaluation. Written Proposal Evaluation.

A second round will be screened by a **panel of experts** of an external evaluation agency to CRIS Cancer, and different from the final evaluation.

Candidacies shall be reviewed and evaluated by **two different evaluators**, in accordance with the criteria specified below in the section on **General evaluation criteria**.

A score from 1-100 will be awarded.

The 10 highest scoring applications or those in the top-scoring 20% will go onto the final evaluation stage.

At the end of this evaluation stage, all candidates that have gone through to the next round will be contacted via email or telephone.

3. Final Evaluation.

The **CRIS International Scientific Committee** will be in charge of the final phase of the evaluation process and will be composed of scientists from various disciplines of maximum international impact.

The evaluation committee shall consist of a Chairperson, a Vice Chair, other members participating in the evaluation, a representative of CRIS, and the technical secretary of the committee.

a. ISC Written Proposal Evaluation

The evaluation committee shall receive the finalist applications from the second evaluation phase. Each application shall be evaluated by **two evaluators**, in accordance with the criteria specified below in the section on **General evaluation criteria**.

Applications will be awarded a score between 1-100. This score is independent of the score obtained in the second stage of evaluation.

Important note: The Evaluation by the International Scientific Committee is independent of the previous evaluation stages. i.e. A very positive evaluation in previous stages does not necessarily guarantee a good evaluation at this stage or to get selected to the interview stage.

b. CRIS Strategy

CRIS cancer Scientific Office shall assign a score to each application considering the CRIS strategy.

c. Patients' evaluation

An evaluation panel composed of cancer patients shall assign a score to each application considering the needs of patients.

d. ISC Interview

The 5 best candidates will be given an online interview by the evaluators. The criteria applied in this interview are set out in the **General evaluation criteria**.

The evaluation committee will meet to discuss the candidates put forward, discuss the most relevant aspects of the project, and prepare the questions to be asked during the interview phase of the candidates selected for interview.

Candidates who are offered an interview should take into account the following:

- Interviews will last about 12 minutes.

- Candidates must **summarise their candidacy**, briefly commenting on their career, their project proposal, the technical approach and the expected results and impact **in 4 minutes**.
- They will be asked questions related to their career and the project, their capacity to develop the proposal, additional resources, etc.
- The candidate must respect the confidentiality and identity of the evaluators that participate in the interview session.

The **Technical Secretary**, in addition to coordinating and monitoring the evaluation process, will perform the following tasks:

- Distribute the candidacies to the evaluators taking into account the expertise of each evaluator and the research area of the candidate.
- Ensure that each evaluator prepares a summary evaluation report for each application received.
- Ensure the evaluators who participate in the evaluation process do not present a conflict of interest with the candidates.
- Draw up a final report. The evaluation committee will meet at the end of the evaluation process and draw up a report listing the chosen candidates.

The best candidates evaluated in this interview stage will be selected for the **CRIS Traslational Physician Programme**.

All candidates who make it into the last assessment round will be notified of the comments resulting from the final discussions of the International Scientific Committee.

General evaluation criteria

In general, three main questions will be taken into account:

- the quality, innovation, and potential of the project
- the excellence, capability, creativity, and potential of the candidate
- the impact of the candidacy.

These criteria will be applied both in the Second Evaluation and in the Final Evaluation.

1. CANDIDATE (50%)

- a. Candidate's motivation and ability to conduct original and creative research.
- b. Candidate's ability to carry out the project independently.
- c. Previous relevant contributions in his/her current or past fields of research.
- d. The candidate's potential to make significant advances in the treatment of cancer.
- e. Candidate's experience and ability to train new researchers.
- f. The candidate's ability to generate intellectual property and develop patents.

2. PROPOSAL (30%)

- a. Originality, innovation, and transformative nature of the project.
- b. Adequacy and degree of innovation of the methodology proposed for the development of the project.
- c. Inter/multidisciplinarity, gender dimension and statistical robustness of the research.
- d. Is the candidate part of/lead or collaborate with an experimental group?
- e. Feasibility of the research project, in terms of expected resources and schedule.
- f. Suitability of the proposed mentor to ensure the success of the project and candidate's growth.
- g. Capacity of the host institution to implement the project.

3. IMPACT (20%)

- a. Impact of the project for the future professional development of the candidate, both within and outside academia.
- b. Degree of translationality of the project and potential impact on clinical practice.
- c. Definition of a dissemination plan, both to the scientific community and to the general public.

In the **International Scientific Committee written proposal evaluation**, which defines the candidates for the **interview**, will also be taken into account whether the project is adequately aligned with the scientific strategy of CRIS Cancer and the strategic centres for CRIS Cancer, that can be downloaded at www.criscancer.org/es/programascris and will be accessible also to candidates through the platform, and the patients' evaluation. The formula used for the selection of candidates to the final interviews is:

- Evaluation of the application by the **International Scientific Committee** (according to the General Evaluation Criteria): 80%.
- Suitability to the strategy of CRIS cancer and its strategic centres: 15%
- Patients' review: 5%

Appeals

Following the publication of the provisional list of beneficiaries of the **CRIS Translational Physician Programme**, there is a period of 5 calendar days during which appeals may be submitted via the platform or by emailing convocatorias@criscancer.org.

The appeals procedure will be strictly confidential. In any case these appeals will result in a scientific re-evaluation by the panel. The independence and objectivity of the assessment is guaranteed by the selection and evaluation process.

Any appeals submitted shall be resolved by an Appeals Committee, which shall notify the candidate of its findings by e-mail within 30 calendar days from the date the appeal is received.

Appointment

The list of Beneficiaries chosen by means of the Evaluation Stage shall be published on the website of CRIS Cancer in the **CRIS Translational Physician Talent Programme** section, as of **31st December 2025**.

In the event that the chosen beneficiaries decide not to take part in the programme, the respective grant shall be awarded to the next highest-scoring candidate as ranked by the Final Evaluation Committee.

The Final Evaluation Committee and CRIS Cancer reserve the right to declare a post null and void if none of the highest-scoring candidates fulfils the requirements of the programme.

The beneficiaries **must begin work at their respective centre by 30 June 2026, the latest**. In duly justified cases of major force, this incorporation could be postponed. Each case will be assessed by CRIS Cancer on an individual basis.

Once the contract is in place, the candidate may transfer to another institution. A formal transfer request must be submitted along with all the documentation requested in the terms and conditions of the call for applications, in addition to an official acceptance from the new host centre. CRIS Cancer must evaluate the transfer request and issue its approval. If the researcher finally moves to a different host institution, the original agreement (signed with the host institution at the submission) would be terminated on the date of the change of institution, and the remaining budget at that date would be returned to CRIS cancer. CRIS contra el cancer would then sign a new agreement with the new institution, specifying the deadlines and budget remaining to be consumed by the project.

Incompatibilities

Candidates must carry out the research project in person, at the host research institution. Clinical practice and research must be carried out on a full-time basis at the host research centre.

This programme is not compatible with other contracts, paid jobs or grants from any other agency, except contracts with the host hospital or institution receiving the candidate. This does not prevent the researcher from applying for any other type of grant or project to fund the research project itself or members of their research group. In any case, CRIS Cancer should be made aware of any joint funding.

This programme is not compatible with permanent employment full-time contracts with any institution other than the hosting institution.

If, at the time of application, the candidate is currently a beneficiary of another grant, programme, or contract, they may still apply to the **CRIS Translational Physician Talent Programme**, provided they are in the last two years of said programme.

The candidate may perform teaching activities, provided they notify CRIS Cancer, and such activities are for a maximum of 80 hours per year.

The submitted research project should not have additional funding from any other private foundation than CRIS Cancer.

The researcher must dedicate a minimum of 50% of his/her research time to the CRIS awarded project.

Any chosen candidates who decide not to take part in the programme may not reapply to subsequent programmes unless their reasons are duly justified and documented.

Any candidates who have been in contact with any member of the evaluation committee regarding issues related to the programme will be immediately excluded from the process and will not be able to reapply in the future.

Any breach of ethical considerations will lead to immediate termination of funding and said individuals will not be allowed to reapply to the programme.

Double Funding and Management of Project-Generated Data is not allowed, considering "double funding" as allocating the same costs, activities, or outputs to more than one source of funding, including but not limited to any other private foundation than CRIS cancer, national funding schemes, regional funds, or other public or private sources.

Obligations

The beneficiary shall undertake to collaborate in communication activities and events organised by the Foundation related to these programmes.

Except for reasons of force majeure, the recipients will undertake to **attend the official awards ceremony for the Programmes.**

CRIS Cancer will request from the host institution a detailed **economic report** breaking down the costs of activities carried out by the candidate. This report is required annually and at the end of the programme.

The host institution receiving the candidate will manage and administer the funds allocated annually by CRIS Cancer to this programme.

At any time, CRIS Cancer reserves the right to request accreditation, asking the candidate to provide the original documents or certified copies of any document indicated in the application or curriculum.

The candidate must submit annually a scientific-technical report in relation to the development of the project. **The report submitted after the second year point will be evaluated by an external agency for funding to continue.**

CRIS Cancer will ask the receiving institution for a detailed financial report of the costs of the activities carried out by the candidate. This report will be delivered each year at the signature of the agreement and at the end of the programme. CRIS Cancer reserves the right to request partial justifications of the economic report in case it needs to present this information to other collaborating entities.

The candidate must submit a letter of commitment from the host institution in which the latter undertakes to respect, at least, 50% of the working time allocated to research.

The institution and mentor undertake to allow, at least, 75% of the publications generated from the project presented to include the candidate as the first or last author.

At the end of the programme, candidates must submit the report of an **economic external audit** justifying the allocation of this funding. This amount can be included in the candidate's budget.

The submitted research project should not have additional funding from any other private foundation than CRIS Cancer.

The Beneficiary must spend a Minimum of 50% of the research time on the CRIS Translational Physician Programme's project.

The Beneficiary agrees that all costs and activities declared under this project funded by CRIS shall not receive funding from any other source and guarantees that no double funding has occurred or will occur during the project lifecycle.

Responsibilities of the Beneficiary

- a. Maintain clear and verifiable financial and operational records to ensure proper allocation of funds and compliance with this clause.
- b. Conduct due diligence to ensure that no costs, activities, or outputs funded by this project are financed by another source.
- c. Regularly review project activities to confirm compliance with CRIS funding rules.

Handling of Data Generated by the Project

- a. All data generated through the implementation of the project funded by CRIS shall be managed in compliance with applicable data management and sharing regulations as outlined in the project agreement.
- b. The Beneficiary agrees to deposit the data in an appropriate and accessible repository, ensuring open access unless otherwise agreed upon with the Granting Authority.
- c. The Beneficiary shall ensure the data is traceable, reusable, and in alignment with the FAIR (Findable, Accessible, Interoperable, and Reusable) principles.
- d. The Beneficiary shall retain ownership of the data but grants the Granting Authority a non-exclusive, royalty-free, and irrevocable license to use, distribute, and reproduce the data for research and policy-making purposes.

Consequences of Non-Compliance

- a. If double funding is detected or if the data management provisions are violated, the Beneficiary shall:
 - i. Immediately refund the amount improperly allocated or address the breach of data management obligations.
 - ii. Be liable for any penalties or legal actions arising from non-compliance.
- b. CRIS cancer reserves the right to terminate this agreement in cases of intentional or repeated violations of this clause.

Data protection and privacy

CRIS Cancer fully complies with current legislation on the protection of personal data.

The personal data of the researchers or any other individual listed in the application documents will be incorporated onto the CRIS database and will only be used for the evaluation of proposals or CRIS information and further grant dissemination. By applying, the participant agrees for information about the Project to be incorporated onto the CRIS database.

For the application and programme evaluation procedure to be conducted, anyone who applies will need to provide their personal data for incorporation onto our database. The purpose of this is to send out notifications concerning the programme and application procedure.

To learn more about the transfer of data and how applicants may exercise their rights, you may request additional information by emailing convocatorias@criscancer.org and you may also exercise your rights of access, correction, or erasure of your personal data, as well as limit or oppose the processing thereof.

Observations

The timeframes and times contained in these terms and conditions are understood to refer to mainland Spain (Central European Time - CET).

The submission of an application for this funding presupposes the candidate's express acceptance of these terms and conditions, as well as the criteria and decisions adopted by CRIS Cancer regarding any queries in the interpretation of the requirements and conditions set forth herein.

The period for obtaining the doctorate can be extended in the event that any of the following situations is duly accredited:

- Maternity/paternity leave following childbirth, permanent adoption, or foster care (provided that the date of birth or judicial/administrative resolution occurred during the scientific career of the candidate, stipulated in the terms and conditions). To be applied:
 - 1 year per child in the case of men.
 - 3 years per child in the case of women.
- Assistance workload. For the calculation of 10 years after defending the PhD, only the time accredited as research time will be taken into account.
- Temporary disability during pregnancy for related reasons. 4 weeks of extension will be applied for each week of leave justified by means of the appropriate documentation.
- Temporary disability due to other causes. A maximum of 1 year extension will be applied.
- Exemptions or reductions in the candidate's working hours due to family illness, dependency, gender-based violence, or terrorist violence. 4 weeks will be applied for each week of activity as a non-professional caregiver justified by means of the appropriate documentation.
- In the case of non-Spanish candidates, participation in compulsory military service. The extension that will be applied corresponds to the period justified by means of the appropriate documentation.

CRIS Cancer will assess how projects integrate the **gender dimension** in both scientific design and team management. This evaluation will focus on two key aspects:

- Gender Dimension in Research and Innovation Content: Projects must address biological and social differences between sexes and genders in their research, i.e. how these differences influence study outcomes, ensuring that methodologies are gender-sensitive, and promoting research findings that are relevant and equitable for all genders. This requirement is evaluated under the scientific aspects during proposal assessments.
- Gender Equality in Research Teams and Leadership: CRIS Cancer will promote gender balance within research teams and decision-making bodies. This includes fostering inclusive environments, encouraging equitable participation in leadership roles, and ensuring that research organizations actively implement gender equality plans. This requirement is evaluated under the management aspects during proposal assessment.

In the event that results susceptible to economic exploitation are derived, the CRIS contra el Cáncer Foundation will have the right to receive a return of the amounts paid. In any case, the parties will sign the appropriate agreement in order to determine such participation.

If the candidate is found to have breached the terms and conditions set out herein, regardless of when this occurs or which stage of the application process or programme the candidate has reached, their candidacy shall be terminated, and any funding granted will be revoked. In the event that the beneficiary does not comply with the aforementioned commitments - or any others included in the conditions of the programme-, CRIS Cancer reserves the right to proceed as appropriate and even request that the beneficiary repays any funding received.

The awarding of funding through this programme, as well as the amount awarded may be conditioned or modified in accordance with the actual resources available to CRIS Cancer at the time of the award.

Under no circumstances may funding for these research programmes be used to cover indirect costs, as CRIS Cancer derives its research funding from contributions from partners, donors, corporations, and legacies.